Indivior PLC (LON:INDV – Get Free Report)’s stock price fell 19.5% during trading on Thursday . The company traded as low as GBX 640 ($8.09) and last traded at GBX 698.90 ($8.83). 1,716,748 shares changed hands during mid-day trading, an increase of 144% from the average session volume of 704,709 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Ratings Changes
Separately, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 1,800 ($22.74) price target on shares of Indivior in a report on Tuesday, December 17th.
Read Our Latest Research Report on Indivior
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
- Five stocks we like better than Indivior
- Investing in Travel Stocks Benefits
- Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
- 3 Grocery Stocks That Are Proving They Are Still Essential
- MarketBeat Week in Review – 02/17 – 02/21
- What Are Some of the Best Large-Cap Stocks to Buy?
- SolarEdge: A Surprising Bright Spot in a Troubled Solar Industry?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.